Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is in Phase III clinical studies `to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants. In addition, its drug candidates include IBP-1118 to prevent retinopathy of prematurity that causes blindness in premature babies; and IBP-1122, indicated to eliminate vancomycin resistant enterococci that cause antibiotic resistant hospital infections. The company was incorporated in 2011 and is based in Stockholm, Sweden.
| 37.92 | |
| 38.52 | |
| - | |
| 38.19 | |
| 37.23 | |
| 21.7-135 | |
| 496 M | |
| 13 018 K | |
| 69 000 | |
| -2.4236 | |
| 1.036 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Message from the CEO Our Phase-III study, the largest of its kind ever conducted, is progressing across 88 hospitals in ten countries. We have now recruited 85% of the patients (1824 out of the plann...
The number of shares and votes in Infant Bacterial Therapeutics AB (publ) has changed due to the recently completed rights issue (for further information, see the company’s press release on 4 July 2...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
